Recruiting

Epcoritamab

Sponsor:

AbbVie

Code:

NCT06830759

Conditions

Diffuse Large B-cell Lymphoma

Follicular Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.

Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.

Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Conditions

Diffuse Large B-cell Lymphoma

Follicular Lymphoma

Study ID

NCT06830759

Start date

Mar 28, 2025

Status verified date

Feb, 2026

Completion date

Sep, 2031

Anticipated

Primary completion date

Sep, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
  • Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
  • The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.

Exclusion Criteria:

  • Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
  • Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Study Design

Enrollment

700 participants

Anticipated

Interventions and Outcome Measures

Arms

Epcoritamab

Participants will receive epcoritamab as prescribed by their physician according to local label.

Primary outcome measure

  • Percentage of Participants Achieving Overall Response (OR) [ Time Frame: Up to approximately 3 years ]

Central Contacts and Locations

Central contacts

Rebekah Taylor

(847) 937-8000rebekah.taylor@abbvie.com

Locations

Cross Cancer Institute /ID# 271504

Recruiting

Edmonton, Alberta, Canada, T6G 1Z2

The Moncton Hospital /ID# 277230

Recruiting

Moncton, New Brunswick, Canada, E1C 6Z8

Eastern Health - General Hospital /ID# 272062

Recruiting

St. John's, Newfoundland and Labrador, Canada, A1B 3V6

Health Sciences North /ID# 274738

Recruiting

Greater Sudbury, Ontario, Canada, P3E 5J1

Kingston General Hospital /ID# 272061

Recruiting

Kingston, Ontario, Canada, K7L 2V7

More Information

Sponsor

AbbVie

Last update posted

Feb 17, 2026

Last verified

Feb, 2026

Keywords

  • Diffuse large B-cell lymphoma
  • Follicular Lymphoma
  • Epcoritamab

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by AbbVie on 2026-02-17.